The past, present, and future of exudative age-related macular degeneration treatment.

Middle East Afr J Ophthalmol · 2012 · PMC3277024 · PMID 22346114

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Ninety-six percent of the combination patients had a 3-month interval during which they did not require a treatment versus 92% of the monotherapy group though combination therapy showed a trend toward reducing Lucentis re-treatments.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.